BackgroundNiclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constit

Figshare2018-06-01 更新20

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

抗病毒药物研发

动物模型药效评估

The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of sub

NIAID Data Ecosystem40

RNA oligonucleotide sequences.

前列腺癌药物研究

转录组研究

The increasing incidence of prostate cancer (PCa) indicates an urgent need for the development of new effective drug therapy. There are limited options to treat the PCa, this study tried to determine

NIAID Data Ecosystem20